Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Free Cash Flow (2016 - 2026)

Champions Oncology has reported Free Cash Flow over the past 17 years, most recently at -$1.5 million for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 526.84% year-over-year to -$1.5 million; the TTM value through Jan 2026 reached $4.1 million, up 388.56%, while the annual FY2025 figure was $7.2 million, 217.14% up from the prior year.
  • Free Cash Flow for Q1 2026 was -$1.5 million at Champions Oncology, up from -$1.7 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $6.8 million in Q2 2025 and troughed at -$4.7 million in Q3 2023.
  • A 5-year average of $213235.3 and a median of $290000.0 in 2022 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: crashed 600.69% in 2023 and later surged 474.83% in 2025.
  • Year by year, Free Cash Flow stood at $2.7 million in 2022, then crashed by 80.98% to $510000.0 in 2023, then plummeted by 155.49% to -$283000.0 in 2024, then tumbled by 504.95% to -$1.7 million in 2025, then rose by 11.74% to -$1.5 million in 2026.
  • Business Quant data shows Free Cash Flow for CSBR at -$1.5 million in Q1 2026, -$1.7 million in Q4 2025, and $554000.0 in Q3 2025.